Exposure to Narrow Band of Green Light Improves Migraine Symptoms
BIDMC Contact: Jennifer Kritz Phone: 617-667-7301; Email: email@example.com
MAY 17, 2016
Green light significantly reduces migraine severity
BOSTON – Light sensitivity, or photophobia, is a frequent symptom of migraine headaches, which affect nearly 15 percent of the world’s population. A new study, led by researchers at Beth Israel Deaconess Medical Center (BIDMC) and published today in Brain, has found that exposing migraine sufferers to a narrow band of green light significantly reduces photophobia and can reduce headache severity.
“Although photophobia is not usually as incapacitating as headache pain itself, the inability to endure light can be disabling,” said lead author Rami Burstein, PhD, Vice Chair of Research in the Department of Anesthesia, Critical Care and Pain Medicine and Academic Director of the Comprehensive Headache Center at BIDMC, as well as the John Hedley-Whyte Professor of Anaesthesia at Harvard Medical School (HMS). “More than 80 percent of migraine attacks are associated with and exacerbated by light sensitivity, leading many migraine sufferers to seek the comfort of darkness and isolate themselves from work, family and everyday activities.”
Five years ago, Burstein and colleagues made the surprising discovery that blue light hurts migraine patients who are blind. This finding prompted the thinking that abnormal sensitivity to light during migraine could be alleviated by blocking blue light. However, because that study involved only blind patients, who cannot detect all colors of light, Burstein and his colleagues devised a way to study the effects of different colors of light on headache in patients without visual impairment.
In this new study, Burstein and colleagues found that of all light to which migraine sufferers are exposed, a narrow band of green light worsens migraine significantly less than all other colors of light and that at low intensities green light can even reduce headache pain. The researchers asked patients experiencing acute migraine attacks to report any change in headache when exposed to different intensities of blue, green, amber and red light. At high intensity of light – as in a well-lit office – nearly 80 percent of patients reported intensification of headache with exposure to all colors but green. Moreover, the researchers found – unexpectedly – that green light even reduced pain by about 20 percent.
To understand exactly why green light causes far less pain to patients with migraines, Burstein and colleagues designed experiments in which they measured the magnitude of the electrical signals generated by the retina (in the eye) and the cortex (in the brain) of these patients in response to each color of light. They found that blue and red lights generated the largest signals in both the retina and the cortex and that green light generated the smallest signals.
Next, applying innovative techniques recently developed by Rodrigo Noseda, PhD, also of BIDMC and Assistant Professor at HMS, they used animal models of migraine to study neurons in the thalamus, an area of the brain that transmits information about light from the eye to the cortex. These neurons were found to be most responsive to blue light and least responsive to green light, explaining why the migraine brain responds favorably to green light.
“These findings offer real hope to patients with migraines and a promising path forward for researchers and clinicians,” said Burstein.
Burstein is now working to develop a more affordable light bulb that emits “pure” (narrow band wavelength) green light at low intensity, as well as affordable sunglasses that block all but this narrow band of pure green light. Currently, the cost of one such light bulb is prohibitively high, and the technology to block all but pure green light in sunglasses is available only in light microscopy, which is also very costly.
In addition to Burstein, coauthors include BIDMC investigators Rodrigo Noseda, Alice Lee, Rony Nir, Carolyn Bernstein, Catherine Buettner, Suzanne Bertisch, Alexandra Hovaguimian and Rodrigo Walker; Boston Children’s Hospital investigator Anne Fulton; Massachusetts Eye and Ear Infirmary investigator Dean Cestari; and Bruce Doran from Diagnosys.
This study was supported by grants from the National Institutes of Health (R37 NS079678 and RO1 NS069847)
About Beth Israel Deaconess Medical CenterBeth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.
BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, MetroWest Medical Center, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and the Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org